摘要
目的:探讨大剂量阿糖胞苷治疗急性髓细胞白血病的临床疗效。方法:回顾性分析笔者所在医院治疗的36例急性髓细胞白血病患者的临床资料。按照随机方式分为观察组和对照组,对照组采取DA、HA或DAE方案诱导至完全缓解,观察组在对照组治疗的基础上,以大剂量阿糖胞苷静脉滴注巩固强化治疗4个疗程,比较两组患者治疗后1、2、3年无病生存率(DFS)。结果:观察组1、2、3年无病生存率均明显优于对照组(P<0.05)。结论:大剂量阿糖胞苷巩固强化治疗,能够安全有效地延长患者生命,减少并发症,提高患者生存质量,临床治疗效果良好。
Objective：To study the use of high-dose cytarabine therapy in acute myeloid leukemia and its clinical efficacy.Method：Retrospective analysis were treated in our hospital in 36 patients with acute myeloid leukemia patients with clinical treatment ease.According to randomly divided into the observation group and the control group, while the control group adopted the DA, HA or DAE regimen induced to complete remission, in the observation group to take control group on the basis of the treatment, with high-dose cytarabine infusion of consolidation therapy for 4 courses, compared two groups of patients at 1 year after treatment, 2 years, 3 years of disease-free survival（DFS）.Result：The observation group werel years, 2 years and 3 years of disease-free survival rate was significantly better than the control group patients（P〈0.05）.Conclusion：To high-dose cytosine arabinoside eonsolidation consolidation therapy is safe and effective, can prolong life, reduce the complications, improve the quality of life of patients, achieved good clinical therapeutic effect.
出处
《中国医学创新》
CAS
2012年第22期4-5,共2页
Medical Innovation of China
